Targeted, Orally Delivered Therapies for Gastrointestinal Diseases
THE SCIENCE
Entero Therapeutics’ product portfolio is built around its three proprietary technologies – latiglutenase, a potentially first-in-class oral biotherapeutic designed to break up gluten and reduce celiac disease symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist with gastrointestinal (GI) indications; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.
LEARN MOREPIPELINE
Entero Therapeutics’ GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by autoimmune malfunction. Disease targets include patient populations with digestive disorders, such as celiac disease, gastroparesis, exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis, and inflammatory bowel diseases such as ulcerative colitis.
IN THE NEWS
|
May 16, 2024
First Wave BioPharma Changes Name to Entero Therapeutics
|
|
May 10, 2024
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
|
|
May 09, 2024
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
|
